{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:17:17Z","timestamp":1773224237496,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.neulet.2018.02.061","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T13:43:39Z","timestamp":1519739019000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pharmacological disruption of the MID1\/\u03b14 interaction reduces mutant Huntingtin levels in primary neuronal cultures"],"prefix":"10.1016","volume":"673","author":[{"given":"Olivia","family":"Monteiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argyrides","family":"Argyrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Pancevac J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Gatfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybille","family":"Krau\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosamund","family":"Langston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susann","family":"Schweiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Uings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neulet.2018.02.061_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/jnnp.66.1.52","article-title":"Differences in duration of Huntington\u2019s disease based on age at onset","volume":"66","author":"Foroud","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.neulet.2018.02.061_bib0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","article-title":"Huntington\u2019s disease: underlying molecular mechanisms and emerging concepts","volume":"38","author":"Labbadia","year":"2013","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"10.1016\/j.neulet.2018.02.061_bib0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.neulet.2018.02.061_bib0020","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group","volume":"72","author":"HD_Collaborative_Research_Group,","year":"1993","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.neulet.2018.02.061_bib0025","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","article-title":"Oligonucleotide therapeutic approaches for Huntington disease","volume":"121","author":"Sah","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.neulet.2018.02.061_bib0030","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","article-title":"Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene","volume":"95","author":"Cha","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.neulet.2018.02.061_bib0035","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"issue":"5334","key":"10.1016\/j.neulet.2018.02.061_bib0040","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.neulet.2018.02.061_bib0045","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1523\/JNEUROSCI.0106-08.2008","article-title":"N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking","volume":"28","author":"Orr","year":"2008","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.neulet.2018.02.061_bib0050","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat. Genet."},{"issue":"18","key":"10.1016\/j.neulet.2018.02.061_bib0055","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","article-title":"Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro","volume":"24","author":"Trushina","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.neulet.2018.02.061_bib0060","doi-asserted-by":"crossref","first-page":"e1002481","DOI":"10.1371\/journal.pgen.1002481","article-title":"A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity","volume":"8","author":"Banez-Coronel","year":"2012","journal-title":"PLoS Genet."},{"issue":"9","key":"10.1016\/j.neulet.2018.02.061_bib0065","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1093\/nar\/gkq1323","article-title":"Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference","volume":"39","author":"de Mezer","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neulet.2018.02.061_bib0070","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1038\/cddis.2013.276","article-title":"Mechanisms of RNA-induced toxicity in CAG repeat disorders","volume":"4","author":"Nalavade","year":"2013","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.neulet.2018.02.061_bib0075","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0896-6273(02)00872-3","article-title":"Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington\u2019s disease and related disorders","volume":"35","author":"Ross","year":"2002","journal-title":"Neuron"},{"issue":"16","key":"10.1016\/j.neulet.2018.02.061_bib0080","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.neulet.2018.02.061_bib0085","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2018.02.061_bib0090","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/ncomms2514","article-title":"Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex","volume":"4","author":"Krauss","year":"2013","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.neulet.2018.02.061_bib0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ng762","article-title":"MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation","volume":"29","author":"Trockenbacher","year":"2001","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.neulet.2018.02.061_bib0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00439-007-0456-6","article-title":"The Opitz syndrome gene product MID1 assembles a microtubule-associated ribonucleoprotein complex","volume":"123","author":"Aranda-Orgilles","year":"2008","journal-title":"Hum. Genet."},{"issue":"1","key":"10.1016\/j.neulet.2018.02.061_bib0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/17460441.2011.537322","article-title":"Fluorescence polarization assays in small molecule screening","volume":"6","author":"Lea","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"issue":"8","key":"10.1016\/j.neulet.2018.02.061_bib0110","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1021\/acschembio.5b00143","article-title":"NanoBRET\u2013A novel BRET platform for the analysis of protein-protein interactions","volume":"10","author":"Machleidt","year":"2015","journal-title":"ACS Chem. Biol."},{"issue":"5","key":"10.1016\/j.neulet.2018.02.061_bib0115","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"43","key":"10.1016\/j.neulet.2018.02.061_bib0120","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.neulet.2018.02.061_bib0125","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.molcel.2010.09.026","article-title":"Regulation of the mTOR complex 1 pathway by nutrients: growth factors, and stress","volume":"40","author":"Sengupta","year":"2010","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.neulet.2018.02.061_bib0130","doi-asserted-by":"crossref","first-page":"13753","DOI":"10.1038\/s41598-017-12974-4","article-title":"Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex","volume":"7","author":"Schweiger","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018301502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018301502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T16:21:59Z","timestamp":1535041319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394018301502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":26,"alternative-id":["S0304394018301502"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2018.02.061","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological disruption of the MID1\/\u03b14 interaction reduces mutant Huntingtin levels in primary neuronal cultures","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2018.02.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}